Sugentech, Inc. Logo

Sugentech, Inc.

Develops advanced in-vitro diagnostic systems for hospitals, clinics, and at-home use.

253840 | KO

Overview

Corporate Details

ISIN(s):
KR7253840003
LEI:
Country:
South Korea
Address:
대전광역시 유성구 테크노2로 206 사무동2층 수젠텍, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sugentech, Inc. is an in-vitro diagnostic (IVD) company that develops and commercializes next-generation diagnostic products by integrating biotechnology (BT), nanotechnology (NT), and information technology (IT). The company specializes in immunochemical diagnostics, leveraging its proprietary platforms for high-level antibody development and high-sensitivity immunoassay technologies. Sugentech offers a range of diagnostic systems tailored to various healthcare settings: multi-immunoblot automation systems for hospitals and medical centers, point-of-care testing (POCT) for smaller clinics, and mobile health (m-Health) solutions for personal, at-home use. Its products are designed for the diagnosis of conditions such as infectious diseases, cardiovascular diseases, and diabetes, aiming to provide personalized and accessible digital healthcare solutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 35.7 KB
2025-09-08 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.2 KB
2025-08-29 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 53.4 KB
2025-08-29 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 42.9 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.7 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.5 MB
2025-04-30 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 30.2 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.3 KB
2025-03-18 00:00
Annual / Quarterly Financial Statement
[첨부추가]사업보고서 (2024.12)
Korean 663.6 KB
2025-03-11 00:00
Audit Report / Information
감사보고서제출
Korean 25.0 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 176.4 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 17.7 KB
2025-03-07 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 167.5 KB
2025-03-07 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 170.6 KB

Automate Your Workflow. Get a real-time feed of all Sugentech, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sugentech, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sugentech, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.